
Market Analysis
TRex Bio Prices $116.7M IPO at Bottom of Range
TL;DR: TRex Bio, a clinical stage biotech targeting autoimmune and inflammatory disease, raised $116.7 million in a U.S. IPO , selling about 8.3 million shares at $14 each. The company had marketed t…
Jeff Barnes, MBA··5 min read

Startups
Robinhood's RVII Fund: What HOOD's Rally Means
TL;DR: Robinhood shares rose 6% on Monday, breaking a four day slide, as the firm opened Robinhood Ventures Fund II (RVII) to retail investors with no income or accreditation requirement, according t…
Jeff Barnes, MBA··6 min read